ERCC1 and ovarian carcinoma: PGPIPN significantly decreased MDR1 and ERCC1 proteins of drug-resistant ovarian cancer cell lines and human primary ovarian cancer cell in a dose-dependent manner (P<0.05 or P<0.01, see in Figure 6).